Poly(allylamine)/tripolyphosphate nanocomplex coacervate as a NLRP3-dependent systemic and mucosal adjuvant for vaccines

聚烯丙胺/三聚磷酸盐纳米复合物凝聚体作为NLRP3依赖性系统性和粘膜疫苗佐剂

阅读:2

Abstract

Nanotechnology plays a crucial role in vaccine development, enabling the design of functional nanoparticles (NPs) that act as both antigen carriers and adjuvants to enhance immune responses. In this study, we evaluated complex coacervate-like NPs composed of poly(allylamine hydrochloride) (PAH) and tripolyphosphate (TPP) as a biocompatible and biosafe platform for systemic and mucosal subunit vaccines. We assessed NP-induced activation of antigen-presenting cells and their adjuvanticity in BALB/c and knockout mice immunized intraperitoneally and intranasally with NP-OVA. In vitro, NPs increased CD86 and MHC II expression and promoted interleukin-1β (IL-1β) and IL-18 secretion via NLRP3 inflammasome activation in macrophages and dendritic cells co-incubated with LPS. Cytokine release occurred through an unconventional autophagosome-dependent pathway, as inhibition of autophagy with 3-methyladenine reduced LPS/NP-induced IL-1β secretion. In vivo, NP-OVA administration induced robust OVA-specific IgG and IgG2a responses, increased IFN-γ secretion by splenocytes, and elevated frequencies of CD4⁺IFN-γ⁺ and CD8⁺IFN-γ⁺ T cells. Comparable responses were observed following intranasal immunization, highlighting the versatility of these NPs as vaccine platforms. Overall, PAH/TPP NPs activate the NLRP3 inflammasome in innate immune cells, promote antigen-presenting cell maturation, enhance cytokine secretion, and induce strong Th1-biased humoral and cellular immune responses. These findings support their potential as a safe dual-function nanoplatform for preventive and therapeutic vaccines against infectious and non-infectious diseases.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。